ライフサイエンスコーパス: hepatocyte growth factor

1 tion of MET or its stimulation by the ligand hepatocyte growth factor.

2 uction of renal epithelial motility with the hepatocyte growth factor.

3 istance of PDAC cells induced by CAF-derived hepatocyte growth factor.

4 ctors, namely fibroblast growth factor 2 and hepatocyte growth factor.

5 d to 14 d by application of soluble VEGF and hepatocyte growth factor.

6 tic liver injury by regulating activation of hepatocyte growth factor.

7 ed by injection of an adenovector expressing hepatocyte growth factor.

8 hanisms, including proteolytic activation of hepatocyte growth factor.

9 everal RTKs, including Met, the receptor for hepatocyte growth factor.

10 the 3'UTR of a short isoform of HGF encoding hepatocyte growth factor.

11 t it suppressed tubulogenesis in response to hepatocyte growth factor.

12 Lungs were evaluated for HGF (hepatocyte growth factor), a protein involved in alveola

13 hepatocyte growth factor, a mediator of CSC migration, w

14 d activity of these and the plasma protease, hepatocyte growth factor activator (HGFA), is associated

15 r Kunitz type 2), a proteolytic inhibitor of hepatocyte growth factor activator (HGFA), which has a s

16 bitor of several serine proteases, including hepatocyte growth factor activator and matriptase.

17 In this study we investigated the roles of hepatocyte growth factor activator inhibitor (HAI)-1 and

18 nate Kunitz-type serine protease inhibitors, hepatocyte growth factor activator inhibitor (HAI)-1 or

19 olled by the Kunitz-type protease inhibitor, hepatocyte growth factor activator inhibitor (HAI-1).

20 mmation mutant caused by an insertion in the hepatocyte growth factor activator inhibitor gene 1 (hai

21 d precursor-like protein 2 (APLP2), bikunin, hepatocyte growth factor activator inhibitor type 2 (HAI

22 mma-catenin were driven by the expression of hepatocyte growth factor activator inhibitor Type I (HAI

23 Hepatocyte growth factor activator inhibitor-1 (HAI-1) i

24 iptase is regulated by its cognate inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1).

25 In this study, we delineated the role of hepatocyte growth factor activator inhibitor-2 (HAI-2) i

26 pression of a serine protease inhibitor, the hepatocyte growth factor activator inhibitor-2, in the l

27 ipitation and LC/MS/MS analysis and isolated hepatocyte growth factor activator inhibitors (HAIs) to

28 In addition, we showed that the hepatocyte growth factor activator, mitogen-activated pr

29 transcriptome differed from that induced by hepatocyte growth factor, although in both cases the sam

30 Hepatocyte growth factor and epidermal growth factors ca

31 Along with hepatocyte growth factor and its receptor MET (HGF-MET),

32 as well as differences in the expression of hepatocyte growth factor and PPAR-gamma, have been demon

33 d other growth-related pathways that involve hepatocyte growth factor and VEGF as well as the down-re

34 (12 CRVO, 6 BRVO) showed baseline levels of hepatocyte growth factor and VEGF of 168.2 +/- 20.1 pg/m

35 hat deserve further study include persephin, hepatocyte growth factor, and endocrine gland VEGF.

36 ssion of vascular endothelial growth factor, hepatocyte growth factor, and hyaluronic acid.

37 factors vascular endothelial growth factor, hepatocyte growth factor, and insulin-like growth factor

38 ls such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpresse

39 -chemokines, fibroblast growth factor-basic, hepatocyte growth factor, and migration inhibition facto

40 s of cultured fibroblasts identified VEGF-A, hepatocyte growth factor, and PDGF-C as candidate secret

41 ospondin 1, connective tissue growth factor, hepatocyte growth factor, and procollagen type I.

42 nteric neurons produce MET, the receptor for hepatocyte growth factor, and that loss of MET activity

43 tors, vascular endothelial growth factor and hepatocyte growth factor, and three markers of osteoblas

44 interleukin-6, tumor necrosis factor-alpha, hepatocyte growth factor, and transforming growth factor

45 lood levels of insulin-like growth factor-1, hepatocyte growth factor, and vascular endothelial growt

46 explains a modest proportion of circulating hepatocyte growth factor, Ang-2, and Tie-2.

47 R) and MET (the receptor tyrosine kinase for hepatocyte growth factors) are cell-surface tyrosine kin

48 graft (total i scores), with upregulation of hepatocyte growth factor at 24 months, indicating a time

49 Blockage of the c-met/hepatocyte growth factor axis attenuates HCC recurrence,

50 ion induced by RF ablation facilitates c-met/hepatocyte growth factor axis-dependent HCC tumor format

51 ion induced by RF ablation facilitates c-met/hepatocyte growth factor axis-dependent HCC tumor format

52 tor tyrosine kinase Sema-PSI in complex with hepatocyte growth factor beta-chain reveals the receptor

53 how VEGF-A stimulates paracrine secretion of hepatocyte growth factor by stromal cells, which induces

54 le RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor in

55 d cellular invasion through stimulation of a hepatocyte growth factor-c-Met signaling circuit, whereb

56 The hepatocyte growth factor/c-MET axis is implicated in tum

57 pathway, insulin-like growth factor pathway, hepatocyte growth factor/c-MET pathway and growth factor

58 s potentially regulated by the key oncogenic hepatocyte growth factor/c-MET pathway in PEL.

59 Moreover, we discovered that hepatocyte growth factor/c-Met signaling is required for

60 ansgenic mice through dual activation of pro-hepatocyte growth factor-cMet-Akt-mTor proliferation/sur

61 In multivariable-adjusted models, sTie-2 and hepatocyte growth factor concentrations were associated

62 factor-beta1], AREG [amphiregulin], and HGF [hepatocyte growth factor]) coupled with T-helper cell ty

63 by ETS1 via this second site is enhanced by hepatocyte growth factor-dependent ETS1 activation, ther

64 transformed human epithelial lung cells in a hepatocyte growth factor-dependent manner.

65 rferon gamma-induced protein 10 (IP-10), and hepatocyte growth factor differentiated between patients

66 but >/=50% of patients showed reductions in hepatocyte growth factor, endocrine gland VEGF, insulin-

67 th factor, insulin-like growth factor-1, and hepatocyte growth factor equally with syngeneic CDCs.

68 in serglycin exhibited diminished levels of hepatocyte growth factor expression and impaired develop

69 r epithelium, which coincided with increased hepatocyte growth factor expression.

70 Furthermore, ICOS-Fc downmodulated hepatocyte growth factor facilitated the epithelial-to-m

71 interleukin-1 receptor antagonist [IL-1ra], hepatocyte growth factor, fatty acid-binding protein 4,

72 24 healthy control subjects, mean levels of hepatocyte growth factor, FGF-13, and IGF-1, but not FGF

73 Hepatocyte growth factor, fibroblast growth factors (FGF

74 genetic proteins, endothelins, steel factor, hepatocyte growth factor, fibroblast growth factors, and

75 Last, we identify hepatocyte growth factor ( HGF) as a novel transcription

76 ted GI and liver GVHD diagnostic biomarkers, hepatocyte growth factor (HGF) and cytokeratin fragment

77 Hepatocyte growth factor (HGF) and epidermal growth fact

78 Their expression is up-regulated by hepatocyte growth factor (HGF) and epidermal growth fact

79 mechanisms of barrier enhancement induced by hepatocyte growth factor (HGF) and evaluated the role of

80 epato-inductive growth factors (GFs) such as hepatocyte growth factor (HGF) and hepato-disruptive GFs

81 ne tyrosine kinase cell surface receptor for hepatocyte growth factor (HGF) and is structurally relat

82 Functional assays identified hepatocyte growth factor (HGF) and its primary receptor

83 Hepatocyte growth factor (HGF) and its receptor (c-Met)

84 Signaling of hepatocyte growth factor (HGF) and its receptor c-Met ca

85 Hepatocyte growth factor (HGF) and its receptor cMET aug

86 Hepatocyte growth factor (HGF) and its receptor MET repr

87 The hepatocyte growth factor (HGF) and its receptor, c-Met,

88 The hepatocyte growth factor (HGF) and its receptor, the tra

89 ained significantly higher concentrations of hepatocyte growth factor (HGF) and pigment epithelium-de

90 We tested the hypothesis that hepatocyte growth factor (HGF) and the HGF receptor MET

91 The hepatocyte growth factor (HGF) and the HGF receptor Met

92 s fate selection to skewing in production of hepatocyte growth factor (HGF) and transforming growth f

93 Hepatocyte growth factor (HGF) and vascular endothelial

94 Hepatocyte growth factor (HGF) and vascular endothelial

95 f LSEC-derived angiocrine factors, including hepatocyte growth factor (HGF) and Wnt2.

96 erythropoietin, stem cell factor (SCF), and hepatocyte growth factor (HGF) are also present at highe

97 en, we identified the aberrant expression of hepatocyte growth factor (HGF) as a crucial element in A

98 e levels of interleukin 6 (IL-6) at 6 hours, hepatocyte growth factor (HGF) at 72 hours, and vascular

99 in vivo glioblastoma models characterized by hepatocyte growth factor (HGF) autocrine or paracrine ac

100 The hepatocyte growth factor (HGF) binding antibody rilotumu

101 The ligand hepatocyte growth factor (HGF) can also be overexpressed

102 ated signaling through binding to its ligand hepatocyte growth factor (HGF) can modulate the apoptosi

103 inical implications was the observation that hepatocyte growth factor (HGF) confers resistance to the

104 Hepatocyte growth factor (Hgf) gene expression was suppr

105 cancer (CRC) cells produces mutations in the hepatocyte growth factor (HGF) gene.

106 Increases in hepatocyte growth factor (HGF) in liver sinusoidal endot

107 atectomy demonstrated enhanced expression of hepatocyte growth factor (HGF) in the liver compared to

108 tokine containing IL-7 and the beta-chain of hepatocyte growth factor (HGF) in the supernatant of cul

109 Hepatocyte growth factor (HGF) induces cell migration an

110 Hepatocyte growth factor (HGF) is a mitogen and insulino

111 Hepatocyte growth factor (HGF) is a mitogen required for

112 Hepatocyte growth factor (HGF) is a multifunctional prot

113 Hepatocyte growth factor (HGF) is a multipotent endogeno

114 eral auditory structures, we discovered that hepatocyte growth factor (Hgf) is expressed in the futur

115 Hepatocyte growth factor (HGF) is responsible for resett

116 Hepatocyte growth factor (HGF) mediated signaling promot

117 f c-Met by EGFR occurs without production of hepatocyte growth factor (HGF) or another secreted facto

118 sion and Akt phosphorylation downstream from hepatocyte growth factor (HGF) or epidermal growth facto

119 Met receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) play an important role in

120 Hepatocyte growth factor (HGF) plays central roles in tu

121 We show that neuregulin 1 (NRG1) and hepatocyte growth factor (HGF) provide resistance to MEK

122 We report that engagement of the hepatocyte growth factor (HGF) receptor c-Met by heart-p

123 with aberrant upregulation of the oncogenic hepatocyte growth factor (HGF) receptor c-MET in PNETs.

124 CD82 has been physically linked to cMet, the hepatocyte growth factor (HGF) receptor, in tumor cells,

125 ated that these endothelial cells supply the hepatocyte growth factor (HGF) required for the chemotac

126 alysis showed that stromal cell secretion of hepatocyte growth factor (HGF) resulted in activation of

127 ion of a TGFbeta gene signature and elevated hepatocyte growth factor (HGF) secretion.

128 We found the roles of hepatocyte growth factor (HGF) signaling in stria vascul

129 Furthermore, inhibition of paracrine factor hepatocyte growth factor (HGF) signaling in vivo suppres

130 Hepatocyte growth factor (HGF) signaling promotes tumor

131 Hepatocyte growth factor (HGF) signaling via c-Met is kn

132 at HACE1 and Rac1 interaction is enhanced by hepatocyte growth factor (HGF) signalling, a Rac activat

133 modeling strategy to systematically unravel hepatocyte growth factor (HGF) stimulated phosphoinositi

134 stain substantial cell-generated forces upon hepatocyte growth factor (HGF) stimulation, consistent w

135 of interleukin (IL)-7 and the beta-chain of hepatocyte growth factor (HGF) that had lymphopoietic st

136 bility of insulin-like growth factor (IGF)-1/hepatocyte growth factor (HGF) to activate resident endo

137 ermore, we describe an NF-kappaB-potentiated hepatocyte growth factor (HGF) to MET proto-oncogene rec

138 l (SC) niche in sarcoma development by using Hepatocyte Growth Factor (HGF) to perturb the niche micr

139 Binding of hepatocyte growth factor (HGF) to the receptor tyrosine

140 cular, we found that the MET receptor ligand hepatocyte growth factor (HGF) was especially active in

141 ascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) with the aim of disruptin

142 owth factor (epithelial growth factor (EGF), hepatocyte growth factor (HGF)) and the activation of th

143 High levels of hepatocyte growth factor (HGF), a healing factor with re

144 igration both in the absence and presence of hepatocyte growth factor (HGF), an established inducer o

145 t ligands, epidermal growth factor (EGF) and hepatocyte growth factor (HGF), and across wide ranges o

146 Gene expression and gene dosage of MACC1, hepatocyte growth factor (HGF), and hepatocyte growth fa

147 basic fibroblast growth factor (FGF-basic), hepatocyte growth factor (HGF), and migration inhibition

148 tivation of c-Met in response to its ligand, hepatocyte growth factor (HGF), and partially blocked th

149 rdiac myocytes and fibroblasts was driven by hepatocyte growth factor (HGF), and platelet activation

150 o drive tumor progression (e.g. VEGF, MMP-9, hepatocyte growth factor (HGF), and RANKL).

151 Epidermal growth factor (EGF), hepatocyte growth factor (HGF), and vascular endothelial

152 Expression of the MET ligand, hepatocyte growth factor (HGF), by tissues innervated by

153 tent, strictly additive, survival effects of hepatocyte growth factor (HGF), ciliary neurotrophic fac

154 that c-Met, the tyrosine kinase receptor for hepatocyte growth factor (HGF), contributes to the pro-t

155 the role of Nogo-B in interleukin-6 (IL-6), hepatocyte growth factor (HGF), epidermal growth factor

156 signaling mediated by c-MET and its ligand, hepatocyte growth factor (HGF), has been implicated in m

157 rosine kinase MET, which is the receptor for hepatocyte growth factor (HGF), has been implicated in o

158 tory protein 1alpha (MIP-1alpha), MIP-1beta, hepatocyte growth factor (HGF), IFN-gamma-inducible prot

159 e transmembrane tyrosine kinase receptor for hepatocyte growth factor (HGF), is known to function as

160 m, glial-derived neurotrophic factor (GDNF), hepatocyte growth factor (HGF), or fibronectin.

161 eptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independen

162 c-Met, a high-affinity receptor for hepatocyte growth factor (HGF), plays a critical role in

163 MET, the receptor for hepatocyte growth factor (HGF), plays an important role

164 eta signaling induces fibroblasts to secrete hepatocyte growth factor (HGF), reciprocally driving col

165 levels of epidermal growth factor (EGF) and hepatocyte growth factor (HGF), reduced FGF, EGFR, and H

166 The overexpression of c-Met and/or hepatocyte growth factor (HGF), the amplification of the

167 tial screening-interleukin 6, interleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of meta

168 be phosphorylated by stimulation of EGF and hepatocyte growth factor (HGF), two promoting factors fo

169 -gamma (MIG), epidermal growth factor (EGF), hepatocyte growth factor (HGF), vascular endothelial gro

170 econd, hepatic RF ablation was performed for hepatocyte growth factor (HGF), vascular endothelial gro

171 gh levels of murine interleukin-6 (IL-6) and hepatocyte growth factor (HGF), whereas cancer cells pro

172 oculomotor neurons to respond to CXCL12 and hepatocyte growth factor (HGF), which are growth promoti

173 conducted in the absence of the MET ligand, hepatocyte growth factor (HGF), which is abundant in the

174 he process involves several factors, such as hepatocyte growth factor (HGF), which restrains hepatic

175 We show that hepatocyte growth factor (HGF), which synergizes with ac

176 ative and angiogenic functions of hEPCs in a hepatocyte growth factor (HGF)-dependent manner.

177 ffector of Met signaling and is required for hepatocyte growth factor (HGF)-induced cell migration.

178 We previously reported that hepatocyte growth factor (HGF)-mediated increases in EC

179 Notably, C1GALT1 attenuation also suppressed hepatocyte growth factor (HGF)-mediated phosphorylation

180 tically inactive forms of RPTP-beta, reduces hepatocyte growth factor (HGF)-stimulated Met tyrosine p

181 we examined the impact of EGFR signaling on hepatocyte growth factor (HGF)-stimulated migration and

182 n and cytotoxicity in response to its ligand hepatocyte growth factor (HGF).

183 in the presence of EMT-inducing signals like Hepatocyte Growth Factor (HGF).

184 tein kinase pathway, causing them to secrete hepatocyte growth factor (HGF).

185 ar matrix, which form tubules in response to hepatocyte growth factor (HGF).

186 at model using a mesenchymal stem cell-based hepatocyte growth factor (HGF).

187 c-MET is the high-affinity receptor for the hepatocyte growth factor (HGF).

188 ial-to-mesenchymal transition in response to hepatocyte growth factor (HGF).

189 factor stimulation by its endogenous ligand, hepatocyte growth factor (HGF).

190 ligand, CSF1, and other cytokines, including hepatocyte growth factor (HGF).

191 osine kinases could be MET, the receptor for hepatocyte growth factor (HGF).

192 vely targets the ligand of the MET receptor, hepatocyte growth factor (HGF).

193 es with ultrasensitive response functions to Hepatocyte Growth Factor (HGF).

194 ansition into an active state in response to hepatocyte growth factor (HGF).

195 The hepatocyte growth factor (HGF)/c-Met signaling axis is d

196 hubs connecting CECs and LSECs included the hepatocyte growth factor (Hgf)/c-Met signaling pathway.

197 Hepatocyte growth factor (HGF)/c-Met supports a pleiotro

198 The relative contribution of hepatocyte growth factor (HGF)/MET and epidermal growth

199 Dysregulation of the hepatocyte growth factor (HGF)/MET pathway promotes tumo

200 Co-occurrence of aberrant hepatocyte growth factor (HGF)/MET proto-oncogene recept

201 The hepatocyte growth factor (HGF)/Met receptor signaling pa

202 Hepatocyte growth factor (HGF)/Met signaling has critica

203 rcuitry is necessary for spatially localized hepatocyte growth factor (HGF)/MET signaling that drives

204 1) is a recently discovered regulator of the hepatocyte growth factor (HGF)/Met/mitogen-activated pro

205 n PPFs: angiopoietin-2 (r = 0.40, P = .001), hepatocyte growth factor (HGF; r = 0.31, P = .02), and e

206 In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .

207 tor-alpha; tumor necrosis factor receptor-1; hepatocyte growth factor; IL-8; elafin, a skin-specific

208 ion study for circulating Ang-2, sTie-2, and hepatocyte growth factor in 3571 Framingham Heart Study

209 ed by higher levels of syndecan-1, VEGF, and hepatocyte growth factor in exosomes secreted by heparan

210 ds to a significantly elevated production of hepatocyte growth factor in hepatic stellate cells posti

211 gration, and a diminished ability to undergo hepatocyte growth factor-induced epithelial-mesenchymal

212 paired apical polarization and inhibition of hepatocyte growth factor-induced tubulogenesis in Tuba k

213 associated with reduced cellular binding of hepatocyte growth factor, inhibition of pERK-1/2 signali

214 ression of the cognate matriptase inhibitor, hepatocyte growth factor inhibitor (HAI)-2.

215 Further, a significant delay in hepatocyte growth factor-initiated signaling, including

216 gen activator inhibitor-1 (PAI-1), resistin, hepatocyte growth factor, interleukin-6 (IL-6), and TNF-

217 ich encodes the receptor tyrosine kinase for hepatocyte growth factor, is a target of miR-449.

218 receptor tyrosine kinase and between MSP and hepatocyte growth factor, it is well established that th

219 ayed a 55-fold increase in the expression of hepatocyte growth factor, known to be involved in myogen

220 activation of Ron, through ligand binding by hepatocyte growth factor-like protein (HGFL), induces th

221 x, and that activation of Ron by its ligand, hepatocyte growth factor-like protein (HGFL), stimulates

222 After binding of its cognate ligand hepatocyte growth factor, Met signaling confers mitogeni

223 Aberrant HGF-MET (hepatocyte growth factor-met proto-oncogene) signaling a

224 Among those, the hepatocyte growth factor/MET (HGF/MET) axis is emerging

225 fficacy with expression levels of MET ligand hepatocyte growth factor, O(6)-methylguanine-DNA methylt

226 gested that patients with high expression of hepatocyte growth factor or unmethylated O(6)-methylguan

227 re inversely associated with baseline plasma hepatocyte growth factor (P = .019).

228 entin (P<0.0001, logistic regression model), hepatocyte growth factor (P<0.0001), alpha-smooth muscle

229 ciated with increased carbonic anhydrase IX, hepatocyte growth factor, placental growth factor, strom

230 plasma angiogenesis factors (angiopoietin 2; hepatocyte growth factor; platelet-derived growth factor

231 2), its soluble receptor Tie-2 (sTie-2), and hepatocyte growth factor play important roles in angioge

232 echanistically, IL-6 trans-signaling induces hepatocyte growth factor production by hepatic stellate

233 After partial hepatectomy, BM SPCs provide hepatocyte growth factor, promote hepatocyte proliferati

234 Hepatocyte growth factor receptor (also known as Met), a

235 Here we focus on the hepatocyte growth factor receptor (c-MET) and the MAP ki

236 The human hepatocyte growth factor receptor (c-MET) signaling path

237 hancing RTKs, including EGF receptor, ErbB2, hepatocyte growth factor receptor (c-Met), EphA2, rearra

238 epidermal growth factor receptor (EGFR), and hepatocyte growth factor receptor (c-Met), improves the

239 epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor (c-MET).

240 like kinase beta, estrogen receptor, and the hepatocyte growth factor receptor (HGFR or MET).

241 the beta2-adrenoceptor with dopamine, or the hepatocyte growth factor receptor (HGFR/c-MET) with an a

242 have transformed the human insulin (hIR) and hepatocyte growth factor receptor (hMET) into glutamate

243 increases in the EGF receptor (EGFR) and the hepatocyte growth factor receptor (Met) expression and a

244 The overexpression and overactivation of hepatocyte growth factor receptor (Met) in various cance

245 f MACC1, hepatocyte growth factor (HGF), and hepatocyte growth factor receptor (MET) were assessed us

246 Crosstalk between the oncogenic RTK hepatocyte growth factor receptor (MET), epidermal growt

247 ork and frequent overexpression of EGFR, the hepatocyte growth factor receptor (MET), pRPS6, and Ki67

248 ntinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endoth

249 ukemia viral oncogene homolog 2 (ERBB2), and hepatocyte growth factor receptor (MET).

250 wth arrest specific protein 6, oncostatin M, hepatocyte growth factor receptor etc.

251 e found to have amplification of EGFR or the hepatocyte growth factor receptor gene (MET) as well.

252 to an autoinhibitory segment observed in the hepatocyte growth factor receptor kinase but different f

253 epithelial cells express high levels of the hepatocyte growth factor receptor Met, and both the rece

254 lathrin exist in complex with either AP-3 or hepatocyte growth factor receptor substrate (Hrs).

255 cosylation of IPT/TIG domains of plexins and hepatocyte growth factor receptor was not affected in TM

256 ppressors, including CCND1 (cyclin D1), MET (hepatocyte growth factor receptor), CDKN2A (cyclin-depen

257 f both normal and cancer cells, and MET, the hepatocyte growth factor receptor, are potential targets

258 epidermal growth factor receptor (EGFR) and hepatocyte growth factor receptor, to intracellular sign

259 orylation of the epidermal growth factor and hepatocyte growth factor receptors, thereby attenuating

260 celerates receptor turnover, whereas loss of hepatocyte growth factor-regulated substrate (Hrs) rescu

261 RT-0 is formed by two subunits known as Hrs (hepatocyte growth factor-regulated substrate) and STAM (

262 ited into an endosomal subdomain enriched in hepatocyte growth factor-regulated tyrosine kinase subst

263 Additionally, hepatocyte growth factor-regulated tyrosine kinase subst

264 n and the ubiquitin-binding ESCRT components hepatocyte growth factor-regulated tyrosine kinase subst

265 that the endosomal proteins Myopic (Mop) and Hepatocyte growth factor-regulated tyrosine kinase subst

266 n as the top positive correlated gene, while hepatocyte growth factor-regulated tyrosine kinase subst

267 fensin 1 and E-cadherin, and upregulation of hepatocyte growth factor-regulated tyrosine kinase subst

268 uired for transport (ESCRT)-0 component Hrs [hepatocyte growth factor-regulated tyrosine kinase subst

269 Furthermore, we identify hepatocyte growth factor-regulated tyrosine kinase subst

270 CLR*RAMP2 was sensitive to overexpression of hepatocyte growth factor-regulated tyrosine kinase subst

271 examined the role of ESCRT-0 component Hrs (hepatocyte growth factor-regulated tyrosine kinase subst

272 d medium derived from myofibroblasts or with hepatocyte growth factor restored clonogenic potential i

273 ybrid cytokine of IL-7 and the beta chain of hepatocyte growth factor (rIL-7/HGFbeta) that stimulates

274 The growth and motility factor Hepatocyte Growth Factor/Scatter Factor (HGF/SF) and its

275 r tyrosine kinase, c-Met, activating it in a hepatocyte growth factor/scatter factor (HGF/SF) indepen

276 Hepatocyte growth factor/scatter factor (HGF/SF) stimula

277 ceptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), modula

278 he MET-tyrosine kinase receptor activated by hepatocyte growth factor/scatter factor (HGF/SF).

279 l cells to the cognate ligand for c-Met, pro-hepatocyte growth factor/scatter factor (proHGF/SF), thr

280 Thirty years later, Met and its ligand hepatocyte growth factor/scatter factor are promising ta

281 ted these epidemiological findings using the hepatocyte growth factor/scatter factor transgenic mouse

282 lls, and is amplified by Met activation with hepatocyte growth factor/scatter factor.

283 ized beads capture secreted molecules (e.g., hepatocyte growth factor secreted by fibroblasts) that a

284 volved in beta-cell proliferation, including hepatocyte growth factor, serotonin synthesis, and integ

285 nist, interferon gamma-inducible protein 10, hepatocyte growth factor, soluble p75 tumor necrosis fac

286 Activation of the Met receptor after hepatocyte growth factor stimulation in vitro promotes a

287 Our results now show that hepatocyte growth factor synthesized by myofibroblasts a

288 interleukin 18 and IP-10 but lower levels of hepatocyte growth factor than those without such abnorma

289 Despite the presence of hepatocyte growth factor, the LECT2 binding causes an an

290 p53-expressing cells were more sensitive to hepatocyte growth factor, the ligand for MET, leading to

291 The ability of hepatocyte growth factor, the ligand for MET, to promote

292 loop that is initiated by cardiac-expressed hepatocyte growth factor to direct T cells into the hear

293 Adding hepatocyte growth factor to induce tubulogenesis, we obs

294 Binding of the hepatocyte growth factor to the cell surface receptor of

295 a combination of angiopoietin-1, angiogenin, hepatocyte growth factor, transforming growth factor-alp

296 ctivation of BAD, and that the resistance of hepatocyte growth factor-treated human melanoma cells to

297 Beclin 1 promoted endosomal recruitment of hepatocyte growth factor tyrosine kinase substrate (HRS)

298 SVPs and CSCs secrete similar amounts of hepatocyte growth factor, vascular endothelial growth fa

299 bound to sSDC1 heparan sulfate chains (i.e. hepatocyte growth factor) was transported to the nucleus

300 ression of uPA regulated the level of active hepatocyte growth factor, which is required for muscle f